Search Results 381-390 of 18799 for alzheimers
These Alzheimer's disease medicines increase levels of chemical messengers in the brain, known as neurotransmitters. These chemical messengers are believed to ...
"When activated, human innate immunity results in inflammation, and previous research on this response to development of Alzheimer's disease has been ...
See educational opportunities and alumni in Nilufer Ertekin-Taner's Genetics of Alzheimer's Disease and Endophenotypes lab at Mayo Clinic.
Aducanumab targets amyloid plaques in the brain that are believed to be an essential component of Alzheimer's disease. "There is certainly great demand for a ...
Alzheimer's Disease Research Center. Director's Message. Dear Mayo Clinic Study of Aging participants,. Thanks to each of you, we have been able to make ...
One of the defining characteristics of Alzheimer's disease is the presence of toxic amyloid plaques that build up in patients' brains.
Polymorphism of the APOE gene is a major genetic determinant of late-onset Alzheimer's disease (AD). APOE4 confers up to a fifteen-fold greater risk of ...
sot: Ronald Petersen, M.D., Ph.D. Director. Mayo Clinic Alzheimer's Disease. Research Center. “Some of these are based in real science that, ...
Learn about publications and news in Nilufer Ertekin-Taner's Genetics of Alzheimer's Disease and Endophenotypes lab at Mayo Clinic.
A new study suggests that a history of concussion involving at least a momentary loss of consciousness may be related to the buildup of Alzheimer's-associated ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.